Free p-cresol sulfate is associated with survival and function of vascular access in chronic hemodialysis patients

Kidney and Blood Pressure Research

Volumn 35, Issue 6, 2013, Pages 583-588

  Chen, Te Chuan ^a   Wang, Chun Yeh ^a   Hsu, Chung Yao ^b   Wu, Chien Hsing ^a   Kuo, Chien Chun ^a   Wang, Ku Chung ^a   Yang, Chih Chau ^a   Wu, Men Tai ^a   Chuang, Feng Rong ^a   Lee, Chien Te ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Hemodialysis; Uremic toxins; Vascular access

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; CLOPIDOGREL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDICAN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 18; PARA CRESOL; PARA CRESOL SULFATE; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ALBUMIN BLOOD LEVEL; ARTERIOVENOUS FISTULA; ARTICLE; DIABETES MELLITUS; ENDOTHELIAL DYSFUNCTION; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HIGH RISK PATIENT; HUMAN; HYPERTENSION; LOW RISK POPULATION; MALE; PRIORITY JOURNAL; SURVIVAL; TREATMENT DURATION; VASCULAR ACCESS;

BIOLOGICAL MARKERS; CRESOLS; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; RETROSPECTIVE STUDIES; SULFURIC ACID ESTERS; VASCULAR ACCESS DEVICES;

EID: 84865300467     PISSN: 14204096     EISSN: 14230143     Source Type: Journal    
DOI: 10.1159/000339709     Document Type: Article

References (25)

1. Roy-Chaudhury P, Sukhatme VP, Cheung AK: Hemodialysis vascular access dysfunction: A cellular and molecular viewpoint. J Am Soc Nephrol 2006; 17: 1112-1127.
2. Meert N, Eloot S, Waterloos M, et al: Effective removal of protein-bound uraemic solutes by different convective strategies: A prospective study. Nephrol Dial Transplant 2009; 24: 562-570.
3. Dou L, Bertrand E, Cerini C, et al: The uremic solutes p -cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Kidney Int 2004; 65: 442-451.
4. Shimizu H, Hirose Y, Nishijima F, Tsubakihara Y, Miyazaki H: ROS and PDGF - receptors are critically involved in indoxyl sulfate actions that promote vascular smooth muscle cell proliferation and migration. Am J Physiol Cell Physiol 2009; 297:C389-C396.
5. Barreto FC, Barreto DV, Liabeuf S, et al, on behalf of European Uremic Toxin Work Group (EUTox): Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol 2009; 10: 1551-1558.
6. Rabelink TJ, de Boer HC, van Zonneveld AJ: Endothelial activation and circulating markers of endothelial activation in kidney disease. Nat Rev Nephrol 2010; 6: 404-414.
7. Lee CT, Kuo CC, Chen YM, et al: Factors associated with blood concentrations of indoxyl sulfate and p -cresol in patients undergoing peritoneal dialysis. Perit Dial Int 2010; 30: 456-463.
8. Jourde-Chiche N, Dou L, Cerini C, Dignat-George F, Brunet P: Vascular incompetence in dialysis patients-protein-bound uremic toxins and endothelial dysfunction. Semin Dial 2011; 24: 327-337.
9. Chang CJ, Ko YS, Ko PJ, et al: Thrombosed arteriovenous fistula for hemodialysis access is characterized by a marked inflammatory activity. Kidney Int 2005; 68: 1312-1319.
10. Zohny SF, El-Fattah MA: Evaluation of circulating vascular endothelial growth factor and soluble adhesion molecules as reliable predictors of native arteriovenous fistula thrombosis in chronic hemodialysis patients. Clin Biochem 2008; 41: 1175-1180.
11. Meyer TW, Hostetter TH: Uremia. N Engl J Med 2007; 357: 1316-1325.
12. Vanholder R, De Smet R, Glorieux G, et al: Review on uraemic toxins: Classification, concentration, and interindividual variability. Kidney Int 2003; 63: 1934-1943.
13. Tumur Z, Shimizu H, Enomoto A, Miyazaki H, Niwa T: Indoxyl sulfate upregulates expression of ICAM-1 and MCP-1 by oxidative stress-induced NF - B activation. Am J Nephrol 2010; 31: 435-441.
14. Lekawanvijit S, Adrahtas A, Kelly DJ, Kompa AR, Wang BH, Krum H: Does indoxyl sulfate, a uraemic toxin, have direct effects on cardiac fibroblasts and myocytes. Eur Heart J 2010; 31: 1771-1779.
15. Nii-Kono T, Iwasaki Y, Uchida M, et al: Indoxyl sulfate induces skeletal resistance to parathyroid hormone in cultured osteoblastic cells. Kidney Int 2007; 71: 738-743.
16. Bammens B, Evenepoel P, Keuleers H, Verbeke K, Vanrenterghem Y: Free serum concentrations of the protein-bound retention solute p -cresol predict mortality in hemodialysis patients. Kidney Int 2006; 69: 1081-1087.
17. Meijers BK, Bammens B, De Moor B, et al: Free p -cresol is associated with cardiovascular disease in hemodialysis patients. Kidney Int 2008; 73: 1174-1180.
18. Barreto FC, Barreto DV, Liabeuf S, et al: Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol 2009; 4: 1551-1558.
19. Evenepoel P, Bammens B, Verbeke K, Vanrenterghem Y: Superior dialytic clearance of - 2 -microglobulin and p -cresol by high-flux hemodialysis as compared to peritoneal dialysis. Kidney Int 2006; 70: 794-799.
20. Pham NM, Recht NS, Hostetter TH, Meyer TW: Removal of the protein-bound solutes indican and p -cresol sulfate by peritoneal dialysis. Clin J Am Soc Nephrol 2008; 3: 85-90.
21. De Smet R, Van Kaer J, Van Vlem B, et al: Toxicity of free p -cresol: A prospective and cross-sectional analysis. Clin Chem 2003; 49: 470-478.
22. Dinarello CA: Interleukin-18 and the pathogenesis of inflammatory diseases. Semin Nephrol 2007; 27: 98-114.
23. Chiang CK, Hsu SP, Pai MF, et al: Interleukin-18 is a strong predictor of hospitalization in haemodialysis patients. Nephrol Dial Transplant 2004; 19: 2810-2815.
24. Yang JY, Huang JW, Chiang CK, et al: Higher plasma interleukin-18 levels associated with poor quality of sleep in peritoneal dialysis patients. Nephrol Dial Transplant 2007; 22: 3606-3609.
25. Lee CT, Ng HY, Hsu CY, et al: Proinflammatory cytokines, hepatocyte growth factor and adipokines in peritoneal dialysis patients. Artif Organs 2010; 34:E222-E229.